Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)

被引：0
|
作者：
van Lokven, T.
Kempcke, R.
Ziemssen, T.
Meergans, M.
机构：
[1] Novartis Pharma GmbH, Nurnberg, Germany
[2] Karl Gustav Carus Univ Hosp, Dresden, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P502
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [21] 5 years safety of fingolimod in real world: Results from PANGAEA, a non-interventional study of RRMS patients in Germany
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 197 - 197
  • [22] First interim results on treatment satisfaction and pharmaco-economic data comparing Fingolimod and first-line therapies in multiple sclerosis patients in Germany (PANGAEA and PEARL)
    Ortler, Sonja
    Ziemssen, Tjalf
    Antonius, van Lokven
    Meergans, Matthias
    JOURNAL OF NEUROIMMUNOLOGY, 2012, 253 (1-2) : 31 - 32
  • [23] Design and Objectives of the Acorn Study: A Non-Interventional Study Evaluating Long-term Safety in Achondroplasia Patients Treated with Vosoritide
    Pimenta, Jeanne M.
    Cohen, Shelda
    Mukherjee, Swati
    Fettes, Fiona
    Jayaram, Kala
    Lausch, Ekkehart
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 127 - 128
  • [24] 36 months PANGAEA: a 5-year non-interventional study of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily clinical practice
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 281 - 282
  • [25] 36 MONTHS PANGAEA: A 5-YEAR NON-INTERVENTIONAL STUDY OF SAFETY, EFFICACY AND PHARMACOECONOMIC DATA FOR FINGOLIMOD PATIENTS IN DAILY CLINICAL PRACTICE
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    VALUE IN HEALTH, 2015, 18 (07) : A749 - A749
  • [26] 24 month PANGAEA: a 5-year non-interventional study of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily clinical practice
    Ziemssen, T.
    Fuchs, A.
    Schwarz, H-J
    van Lokven, T.
    Cornelissen, C.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 115 - 116
  • [27] 36 months PANGAEA: A 5-year non-interventional study of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily clinical practice
    Ziemssen, T.
    Albrecht, H.
    Klotz, L.
    Schmidt, S.
    Schwarz, H. -J.
    Tackenberg, B.
    Cornelissen, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 28 - 28
  • [28] Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study
    Deri, Norma
    Barboza, Andres
    Vrech, Carlos
    Rey, Roberto
    Burgos, Marcos
    Fiol, Marcela
    CalvoVildoso, Cristian
    Patrucco, Liliana
    Jose, Gustavo
    Aliberti, Paula
    Chirico, Daniela
    Federico, Maria B.
    Seifer, Gustavo
    Piedrabuena, Raul
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 83
  • [29] Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study
    Paolicelli, Damiano
    Manni, Alessia
    Direnzo, Vita
    D'Onghia, Mariangela
    Tortorella, Carla
    Zoccolella, Stefano
    Trojano, Maria
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (10): : 1131 - 1136
  • [30] 36 months PANGAEA-A 5-year non-interventional study of safety, efficacy, and pharmacoeconomic data for fingolimod patients in daily clinical practice
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L. Luisa
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP19 - NP20
12345